In comparison, in our study, overall, 37% of patients with multiple primary cancers who underwent multi-gene panel testing were found to carry pathogenic mutations; 24% had mutations in the mismatch repair and BRCA1/2 genes, while 13% had mutations in other cancer predisposition genes - more than two times than in the European study. This evidence concerns the gene BRCA1 and cancer.